Skip to main content
OpenTrials
Completed

NCT Number: NCT04559529

Pharmacological Modulation of Hippocampal Activity in Psychosis 2

The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity in people with psychotic disorders. Specifically, the investigators will utilize two functional magnetic resonance imaging (MRI) techniques: 1) blood-oxygen-level-dependent (BOLD) contrast will assess activity with a visual scene processing task that engages the anterior hippocampus and 2) arterial spin labeling (ASL) will assess baseline activity. Previous studies in people with psychotic disorders have shown that the hippocampus is hyperactive and more activity correlates with worsening of clinical symptoms. Therefore, the aim of this study is to use an intervention to further understand the underlying mechanisms of the hippocampus in psychosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for psychosis subjects

  • Men and women age 18 - 65.
  • Communicative in English.
  • Provide voluntary, written informed consent.
  • Physically healthy by medical history.
  • BMI > 17.5 and < 45.
  • Diagnosis of a psychotic disorder confirmed by Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID) or diagnostic interview with a trained clinician.
  • Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.
  • For females, no longer of child-bearing potential, or agreeing to practice effective contraception during the study (e.g., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository; male partner sterilization; or true abstinence when this is in line with the preferred and usual lifestyle of the subject); and,
  • For females of child-bearing potential, must have a negative urine pregnancy test before MRI and drug administration.
  • Not breastfeeding/nursing at time of screening or at any time during the study.

Inclusion criteria

for healthy controls

  • All of the above except for subjects will be psychiatrically healthy and not taking psychotropic or potentially psychoactive prescription medication.

----

Exclusion criteria

Exclusion criteria

for psychosis subjects

  • Age less than 18 or greater than 65.
  • Not communicative in English.
  • Unable to provide written informed consent.
  • Current medical or neurological illness.
  • History of severe head trauma.
  • BMI < 17.5 or > 45.
  • Meets criteria for diagnosis of substance or alcohol use disorder within the past month.
  • Positive urine pregnancy test during the study.
  • Breastfeeding/nursing at time of screening or at any time during the study.
  • Conditions that preclude MR scanning (as defined in the Screening Form)
  • Conditions that preclude study drug administration (as defined in the Screening Form)

Exclusion criteria

for healthy controls

All of the above and in addition:

  • Current use of psychotropic or potentially psychoactive prescription medication.
  • Major psychiatric disorder as determined by Diagnostic and Statistical Manual -5 (major depression, bipolar disorder, obsessive compulsive disorder, post-traumatic stress disorder, etc)

Treatment and study plan

Levetiracetam (LEV) 500 mg

Drug

The levetiracetam pill will look just like the placebo pill.

Other names: Keppra

Placebo

Drug

The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.

Primary outcomes

  1. Hippocampal Activity (Arterial Spin Labeling [ASL] Study) After Levetiracetam (LEV)

    Time frame: 2 hours after LEV administration

    ASL signal after LEV, using Magnetic Resonance Imaging (MRI) scanning of the brain. ASL measures cerebral blood flow, which is linked to neuronal metabolism and functions as a proxy for neuronal activity.

  2. Hippocampal Activity (Arterial Spin Labeling [ASL] Study) After Placebo

    Time frame: 2 hours after placebo administration

    ASL signal after placebo, using Magnetic Resonance Imaging (MRI) scanning of the brain. ASL measures cerebral blood flow, which is linked to neuronal metabolism and functions as a proxy for neuronal activity.

  3. Hippocampal Recruitment (Blood-Oxygen-Level-Dependent [BOLD] Study) After Levetiracetam (LEV)

    Time frame: 2 hours after LEV administration

    BOLD signal after LEV, using Magnetic Resonance Imaging (MRI) scanning of the brain. This method reflects changes in oxygenation of blood in the brain during a scene-processing task that engages, or recruits, the hippocampus.

  4. Hippocampal Recruitment (Blood-Oxygen-Level-Dependent [BOLD] Study) After Placebo

    Time frame: 2 hours after placebo administration

    BOLD signal after placebo, using Magnetic Resonance Imaging (MRI) scanning of the brain. This method reflects changes in oxygenation of blood in the brain during a scene-processing task that engages, or recruits, the hippocampus.

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Sep 23, 2020
Registry last updated
Feb 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.